Vyne Therapeutics Inc
VYNE0.304USD
-0.006-1.87%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
6.02MMarket Cap
LossP/E TTM
More Details of Vyne Therapeutics Inc Company
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Company Info
Ticker SymbolVYNE
Company nameVyne Therapeutics Inc
IPO dateJan 25, 2018
CEOMr. David Domzalski
Number of employees13
Security typeOrdinary Share
Fiscal year-endJan 25
Address685 Route 202/206 N., Suite 301
CityBRIDGEWATER
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code08807
Phone18007757936
Websitehttps://vynetherapeutics.com/
Ticker SymbolVYNE
IPO dateJan 25, 2018
CEOMr. David Domzalski
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
116.19K
-2.86%
Mr. Patrick G. Lepore
Mr. Patrick G. Lepore
Lead Independent Director
Lead Independent Director
51.47K
--
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
42.30K
-5.45%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Sharon Barbari
Ms. Sharon Barbari
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
116.19K
-2.86%
Mr. Patrick G. Lepore
Mr. Patrick G. Lepore
Lead Independent Director
Lead Independent Director
51.47K
--
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
42.30K
-5.45%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Sharon Barbari
Ms. Sharon Barbari
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2024
FY2023
FY2022
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
Royalty revenues
501.00K
0.00%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Royalty revenues
501.00K
0.00%
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Cormorant Asset Management, LP
5.38%
Access Industries, Inc.
4.38%
Citadel Advisors LLC
4.08%
Acorn Capital Advisors, LLC
2.89%
Delaware Street Capital, L.L.C.
2.73%
Other
80.53%
Shareholders
Shareholders
Proportion
Cormorant Asset Management, LP
5.38%
Access Industries, Inc.
4.38%
Citadel Advisors LLC
4.08%
Acorn Capital Advisors, LLC
2.89%
Delaware Street Capital, L.L.C.
2.73%
Other
80.53%
Shareholder Types
Shareholders
Proportion
Hedge Fund
22.17%
Investment Advisor
8.70%
Corporation
4.38%
Investment Advisor/Hedge Fund
1.61%
Individual Investor
1.46%
Private Equity
1.24%
Research Firm
0.59%
Venture Capital
0.22%
Other
59.63%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
84
9.46M
56.76%
-1.30M
2025Q1
81
9.36M
56.20%
-1.38M
2024Q4
92
9.37M
63.49%
-533.87K
2024Q3
88
8.98M
61.30%
-594.32K
2024Q2
89
9.65M
66.73%
+287.65K
2024Q1
92
9.64M
67.66%
+101.95K
2023Q4
101
10.22M
72.71%
+4.63M
2023Q3
117
471.27K
14.37%
-340.06K
2023Q2
135
501.83K
15.37%
-314.68K
2023Q1
168
461.83K
16.95%
-412.21K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Access Industries, Inc.
1.12M
6.7%
--
--
Feb 14, 2025
Citadel Advisors LLC
1.10M
6.6%
-130.13K
-10.58%
Mar 31, 2025
Acorn Capital Advisors, LLC
785.94K
4.72%
+328.97K
+71.99%
Mar 31, 2025
Delaware Street Capital, L.L.C.
696.47K
4.18%
--
--
Sep 30, 2024
Adage Capital Management, L.P.
344.13K
2.06%
+190.00K
+123.27%
Mar 31, 2025
Dafna Capital Management, LLC
636.10K
3.82%
+636.10K
--
Mar 31, 2025
Kennedy Capital Management LLC
78.04K
0.47%
+176.00
+0.23%
May 31, 2025
The Vanguard Group, Inc.
475.65K
2.85%
+521.00
+0.11%
Mar 31, 2025
Palo Alto Investors LP
445.43K
2.67%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
Date
Type
Ratio
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
